CAR-T immunotherapy

Surgery, radiotherapy, chemotherapy, and precision therapy make up the four established pillars of cancer treatment.

Cancer Immunotherapy has been hailed as the ‘fifth pillar’ of cancer treatment. At the forefront of this ‘fifth pillar’ is CAR-T-Cell Immunotherapy, which is personalized to each patient using their own T-Cells. CAR-T-Cell Immunotherapy aims to improve the immune system’s intrinsic capabilities to identify and attack cancer cells while leaving healthy cells undamaged.

Chimeric antigen receptor – T cell (CAR-T) therapy, is one of the most promising treatment breakthroughs in recent years. It uses genetically engineered immune T cells to recognize specific proteins on tumor cells. CAR-T clinical trials have shown huge remission rates, of up to 94%, in severe forms of blood cancer. This is particularly impressive considering the fact that most CAR-T clinical trials recruit cancer patients that have not responded to many if not all other available treatments.

When your body does not respond well to conventional therapies, CAR-T provides chance for you to fight back and empowering you with a real chance to rewrite your story.

When T-cells attack harmful cells or viruses, they are programmed to remember them if they attack again. CAR-T-cells are no different. If the process works correctly, they are meant to be on 24/7 duty for the rest of the patient’s life. Theoretically, if cancer cells re-emerge, the CAR-T-cells will recognize them and kill them, even without the patient knowing it. CAR-T cells are designed to have long-lasting effects with one treatment; once you infuse the engineered T-cells, they remain in the body. It is as you are having a living drug in your body for the rest of your life.

Patients with an immediately life-threatening condition or serious disease may be granted an expanded access pathway for CAR-T-Cell or other immunotherapies, as provided by the USFDA and regulatory bodies in other countries, under their respective provisions for compassionate use of investigational treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

All treatments with CAR-T products prepared and supplied by our group have been approved by the Ministry of Health of Malaysia and the ministries of health of all other countries where we have supplied the CAR-T products.

Patients eligible for CAR-T Cell Immunotherapy must meet the following criteria:

• Patients must be well enough to undertake leukapheresis and receive CAR-T therapy.
• The tumor must express the appropriate marker (for example CD19, or CD22).
• The Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1.
• No disease complications or chemo-toxicity, such as, infection, active GVHD, hyperleukocytosis, severe extra medullary disease.
• The last dose of chemotherapy and/or steroid is at least 2 weeks prior to leukapheresis; when in doubt, a T-Cell activation test shall be performed.
• Patient’s tumor burden is as low as possible. In patients with uncontrolled or accelerating tumor burden, bridging chemotherapy should be performed first (apheresis can be done prior to commencing the chemotherapy).

If any of the above requirements are not met, there is an option for the patient to freeze their T-Cells for future use once treatment can proceed.

• Patient Educational Materials
• Doctor’s Educational Materials
• Free Pre-treatment Assessment
• Comprehensive Auxiliary support for treatments in Malaysia
• Post Treatment Monitoring

The Vamos group of companies is engaged in life-cell therapies since 2016. We provide cutting-edge biotechnology products to both hospitals and patients seeking the most effective cancer treatments. Our suite of T-cell based immunotherapies and services are highly accurate, personalized, and focused on providing the most effective treatments based on highest quality standards and at the lowest cost possible.

Our group provides the following services:

• Production and supply of autologous CAR-T cells for CAR-T treatments provided by hospitals in Malaysia and internationally.
• Medical tourism and auxiliary services related to hosting of international patients taking CAR-T treatments in Malaysia.

• Our group is the only provider of CAR-T therapy in Malaysia for blood cancers.
• Our CAR-T therapy is approved by the Malaysian Ministry of Health.
• All patients that participated in the clinical trial achieved complete remission are live a life free of cancer (with exception of 3 patients that passed away before receiving the actual CAR-T treatment).
• 6 of the top hospitals in Malaysia provide CAR-T treatments with our products.
• So far, we have treated more than 100 number of patients with stage 4 cancer, and the success rate of our CAR-T therapy is over 90%.
• Up to date, all patients treated with our CAR-T therapy have been treated successfully and without experienced any severe side effects.
• The quality of our CAR-T therapy is second to none, while the cost of our therapy is possibly the lowest cost in healthcare worldwide.
• In addition to CAR-T therapy (for both blood and solid cancers), we also provide DC therapy, CIK therapy, and DC-CIK therapy for solid cancers. Together with our clinical trial partner hospital, our group has conducted more than 2,000 DC, CIK & DC-CIK treatments.